Contents
Existing models of trade with the EU
Norway: the European Economic Area and single market integration
Canada: a free trade agreement focusing on mutual recognition
Brexit and the Department for Health and Social Care’s Single Departmental Plan
2 Protecting and enhancing the UK’s position in Europe and globally
UK’s position and influence in Europe
Medicines and Healthcare products Regulatory Agency
Influence of the UK Government, national bodies and institutions in European regulations
(i) Patients should not be disadvantaged
(ii) Innovators should be able to get their products into the UK market quickly
(iii) UK must continue to play a leading role promoting public health
4 Aligning with the EU on market authorisation and regulation
Regulatory alignment with the EU after Brexit
Batch testing, QPs and Good Manufacturing and Distribution Practices
The UK’s relationship with the EMA
5 Continued collaboration in other areas of the life science sector
Research and development and clinical trials
Current participants in clinical trials
Continued participation in clinical trials
Regulatory alignment over EU rules for data protection
Research and collaboration networks
Research and development funding
Access to EU pharmacovigilance systems
Trade, customs and supply chains
Stockpiling and time-sensitive supply chains
Medical radioisotopes and Euratom
World Trade Organisation (WTO) rules
Conclusions and recommendations
List of Reports from the Committee during the current Parliament
Published: 21 March 2018